Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation

Cancer Biology and Therapy

Volumn 9, Issue 11, 2010, Pages 903-907

  Ma, Haiqing ^a   Zhang, Yaojun ^a   Wang, Qijing ^a   Li, Yongqiang ^a   He, Jia ^a   Wang, Hui ^a   Sun, Jiancong ^a   Pan, Ke ^a   Chen, Minshan ^a   Xia, Jianchuan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Adoptive cell immunotherapy; Hepatocellular carcinoma; Radiofrequency ablation; Recombinant human fibronectin fragment; T lymphocyte subsets

Indexed keywords

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KILLER CELL; LIVER CELL CARCINOMA; LYMPHOCYTE; MALE; PATIENT SAFETY; RADIOFREQUENCY ABLATION; RETRONECTIN ACTIVATED KILLER CELL; TUMOR RECURRENCE; TUMOR VOLUME; ADOPTIVE IMMUNOTHERAPY; CATHETER ABLATION; CELL CULTURE; CELL STRAIN HEPG2; CLINICAL TRIAL; CYTOLOGY; CYTOTOXICITY; CYTOTOXICITY TEST; IMMUNOLOGY; IMMUNOPHENOTYPING; LIVER TUMOR; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE;

FIBRONECTIN; GAMMA INTERFERON; LEUKOCYTE ANTIGEN; RECOMBINANT PROTEIN; RETRONECTIN;

ADULT; ANTIGENS, CD; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CELL LINE, TUMOR; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FIBRONECTINS; HEP G2 CELLS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 79952276385     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.11.11697     Document Type: Article

References (20)

1. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232:10-24. (Pubitemid 30456545)
2. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002; 17:889-96.
3. Maksan SM, Araib PM, Ryschich E, Gebhard MM, Schmidt J. Immune escape mechanism: defective resting and stimulated leukocyte-endothelium interaction in hepatocellular carcinoma of the rat. Dig Dis Sci 2004; 49:859-65.
4. Fatourou EM, Koskinas JS. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. Expert Rev Anticancer Ther 2009; 9:1499-510.
5. Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 2008; 31:63-71.
6. Lee HJ, Lee YS, Kim HS, Kim YK, Kim JH, Jeon SH, et al. Retronectin enhances lentivirus-mediated gene delivery into hematopoietic progenitor cells. Biologicals 2009; 37:203-9.
7. Muraki N, Ideno M, Nukaya I, Sagawa H, Enoki T, Kato I. T cell expansion using RetroNectin (I): useful method to expand T cells, characterized by high portion of naive T-like cells. Sixty-Fifth Annual Meeting of the Japanese Cancer Association; 29 September 2006; Yokohama, Kanagawa. Japanese Cancer Association: Shinjuku, Tokyo 2006.
8. Ideno M, Muraki N, Nukaya I, Sagawa H, Enoki T, Kato I. T cell expansion using RetroNectin (II): RN-T cells contain high portion of naive T-like cells and show high ability of antigen recognition. Sixty-Fifth AnnualMeeting of the Japanese Cancer Association; 29 September 2006; Yokohama, Kanagawa. Japanese Cancer Association: Shinjuku, Tokyo 2006.
9. Curley SA. Radiofrequency ablation of malignant liver tumors, Ann Surg Oncol 2003; 10:338-47.
10. Garcea G, Lloyd TD, Aylott C, Maddern G, Berry DP. The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours. Eur J Cancer 2003; 39:2150-64.
11. den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, Adema GJ. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004; 64:4024-9.
12. Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 2006; 66:1139-46. (Pubitemid 43165983)
13. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356:802-7.
14. Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M. Perforin and IFNgamma are involved in the antitumor effects of antibody-targeted superantigens. J Immunol 1998; 160:5309-13. (Pubitemid 28267818)
15. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369:31-7.
16. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-12. (Pubitemid 129515761)
17. + effector and memory T cell generation. Nat Immunol 2003; 4:835-42.
18. + T cells. J Exp Med 1997; 186:1407-18.
19. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation and maintenance. Annu Rev Immunol 2004; 22:745-63.
20. + T cells. J Clin Invest 2005; 115:1616-26.